



RECEIVED  
MAY 14 #9

MAY 22 2003

TECH CENTER 1600/2900

ATTORNEY DOCKET NO. 50291/002001

Certificate of Mailing: Date of Deposit: May 16, 2003

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Kathy Meuse

Printed name of person mailing correspondence

Kathy Meuse

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Robert Chalifour et al.

Art Unit: 1614

Serial No.: 10/009,122

Examiner: Not yet assigned

Filed: June 18, 2002

Customer No.: 21559

Title: Stereoselective Antifibrillogenic Peptides and Peptidomimetics  
Thereof

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

REVOCATION AND NEW POWER OF ATTORNEY

Under 37 C.F.R. § 3.73(b), Neurochem, Inc., a corporation, certifies that it is the assignee of 100% of the right, title, and interest in the patent application identified above by virtue of an assignment from the inventors named on the application. A copy of the assignment, which is being recorded in connection with this application today, is enclosed.

The undersigned, whose title is supplied below, is empowered to act on behalf of the assignee.

attorney previously granted in the application and appoints: Paul T. Clark, Reg. No. 30,162; Karen L. Elbing, Ph.D., Reg. No. 35,238; Kristina Bieker-Brady, Ph.D., Reg. No. 39,109; Susan M. Michaud, Ph.D., Reg. No. 42,885; James D. DeCamp, Ph.D., Reg. No. 43,580; Sean J. Edman, Reg. No. 42,506; Vicki L. Healy, Ph.D., Reg. No. 48,343; Jan Tittel, Ph.D., Reg. No. 52,290; J. Cooper McDonald, Ph.D., Reg. No. 52,011; Jeffrey Ellison, Ph.D., Reg. No. 51,649; and Michael J. Belliveau, Ph.D., Reg. No. 52,608 with full power of substitution and revocation, to prosecute the application and to transact all business in the United States Patent and Trademark Office connected therewith.


All correspondence regarding the application should now be sent to:

Karen L. Elbing, Ph.D.  
Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110

Telephone: 617-428-0200  
Facsimile: 617-428-7045  
Customer No.: 21559

Date: 31/03/2003

Respectfully submitted,



Claude Michaud  
Senior Vice President, Finance & Chief  
Financial Officer  
Neurochem, Inc.



21559

PATENT TRADEMARK OFFICE

**COPY****ASSIGNMENT**

For valuable consideration, we,

| Full Name of Assignor | Address  |
|-----------------------|--|
| Robert Chalifour      | 332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 Canada |
| Francine Gervais      | 1003 Bellevue, Ile Bizard, Québec H9C 2X5 Canada       |
| Ajay Gupta            | 255 St. Louis, Pointe Claire, Québec H9R 5L6 Canada    |

hereby assign to

| Full Name of Assignee | Business Address  |
|-----------------------|---|
| Neurochem Inc.        | 7220, rue Frederick-Banting, Bureau 100, Ville Saint Laurent, Québec, Canada, H4S 2A1 |

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more patent applications identified as:

| Title of Application   | Filing Date   | Serial Number   |
|--|---------------|---|
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 5, 1999   | U.S. Serial No. 60/132,592  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | PCT/CA00/00515  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | June 18, 2002 | U.S. Serial No. 10/009,122  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Australian Application No. 45298/00   |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Canadian Application No. 2,388,092  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | European Patent Application No. 00926599.2  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Hong Kong application corresponding to European Patent Application No. 00926599.2 |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Israel Application No. 146009   |

|  |             |                                      |
|--|-------------|--------------------------------------|
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000 | Japanese Application No. 2000-616237 |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000 | New Zealand Application No. 515807   |

This assignment includes said applications, any and all patent applications (including continuation applications, divisional applications, continuation-in-part applications, and reissue applications), patents, reissues, extensions, utility models, and design registrations granted for any of said inventions or improvements, in any country, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment is effective as of the filing dates of each of the listed applications.

IN WITNESS WHEREOF, I hereto set my hand and seal at \_\_\_\_\_, this \_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_.

L.S.

Robert Chalifour

Witness #1:

\_\_\_\_\_

signature

\_\_\_\_\_

printed name

\_\_\_\_\_

date

Witness #2:

\_\_\_\_\_

signature

\_\_\_\_\_

printed name

\_\_\_\_\_

date

IN WITNESS WHEREOF, I hereto set my hand and seal at \_\_\_\_\_,  
this \_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_.

L.S.

Francine Gervais

Witness #1: \_\_\_\_\_  
signature \_\_\_\_\_ printed name \_\_\_\_\_ date \_\_\_\_\_

Witness #2: \_\_\_\_\_  
signature \_\_\_\_\_ printed name \_\_\_\_\_ date \_\_\_\_\_

IN WITNESS WHEREOF, I hereto set my hand and seal at \_\_\_\_\_, Montreal, Quebec,  
this 11<sup>th</sup> day of April, 2003.

Ajay Gupta Ajay Gupta L.S.

Witness #1: Leontine Teryer April 11, 2003  
signature \_\_\_\_\_ printed name \_\_\_\_\_ date \_\_\_\_\_

Witness #2: Michael Journeais April 11, 2003  
signature \_\_\_\_\_ printed name \_\_\_\_\_ date \_\_\_\_\_

**ASSIGNMENT****COPY**

For valuable consideration, we,

| Full Name of Assignor | Address  |
|-----------------------|--|
| Robert Chalifour      | 332 Place Ladouceur, Ile Bizard, Québec H9C 1T4 Canada |
| Francine Gervais      | 1003 Bellevue, Ile Bizard, Québec H9C 2X5 Canada       |
| Ajay Gupta            | 255 St. Louis, Pointe Claire, Québec H9R 5L6 Canada    |

hereby assign to

| Full Name of Assignee | Business Address  |
|-----------------------|---|
| Neurochem Inc.        | 7220, rue Frederick-Banting, Bureau 100, Ville Saint Laurent, Québec, Canada, H4S 2A1 |

and to its successors and assigns (collectively hereinafter called "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements which are subject of one or more patent applications identified as:

| Title of Application   | Filing Date   | Serial Number   |
|--|---------------|---|
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 5, 1999   | U.S. Serial No. 60/132,592  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | PCT/CA00/00515  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | June 18, 2002 | U.S. Serial No. 10/009,122  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Australian Application No. 45298/00   |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Canadian Application No. 2,388,092  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | European Patent Application No. 00926599.2  |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Hong Kong application corresponding to European Patent Application No. 00926599.2 |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000   | Israel Application No. 146009   |

|  |             |                                      |
|--|-------------|--------------------------------------|
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000 | Japanese Application No. 2000-616237 |
| Stereoselective Antifibrillogenic Peptides and Peptidomimetics Thereof | May 4, 2000 | New Zealand Application No. 515807   |

This assignment includes said applications, any and all patent applications (including continuation applications, divisional applications, continuation-in-part applications, and reissue applications), patents, reissues, extensions, utility models, and design registrations granted for any of said inventions or improvements, in any country, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations, and like rights of exclusion, and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation, to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements, and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment. This assignment is effective as of the filing dates of each of the listed applications.

IN WITNESS WHEREOF, I hereto set my hand and seal at Ville Saint Laurent,  
this 1<sup>st</sup> day of April, 2003.

Robert Chalifour L.S.  
Robert Chalifour

Witness #1: G Sebastian GIOVANNA SEBASTIANI Apr. 1, 2003  
signature printed name date

Witness #2: Richard McLaughlin Richard McLaughlin Apr. 11, 2003  
signature printed name date

IN WITNESS WHEREOF, I hereto set my hand and seal at Dorval,  
this 31 day of MARCH, 2003.

Francine Gervais L.S.  
Francine Gervais

Witness #1: Pierre Peloso LINÉ PELOSSE 31-03-2003  
signature printed name date

Witness #2: Denis Garneau DENIS GARNEAU 31-03-03  
signature printed name date

IN WITNESS WHEREOF, I hereto set my hand and seal at \_\_\_\_\_,  
this \_\_\_\_\_ day of \_\_\_\_\_, 20\_\_\_\_.

Ajay Gupta L.S.

Witness #1: \_\_\_\_\_  
signature printed name date

Witness #2: \_\_\_\_\_  
signature printed name date